LobbyingViron Therapeutics lobbying by quarter
Viron Therapeutics's latest lobbying report covers Q1 2023, at $50K. Its first report covers Q4 2022; the issues it reports most are Medical/Disease Research/Clinical Labs.
Viron Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $75K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $0 | 0 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medical research and clinical labs$125K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)2 reports
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Ben Barnes Group | $125K | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/04/11for Q1 2023 | Ben Barnes Group | $50K |
| 23/01/07for Q4 2022 | Ben Barnes Group | $75K |